Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update Nov 14, 2023
Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection Nov 2, 2023
Acurx Pharmaceuticals to Discuss Third Quarter 2023 Financial Results and Provide Business Update Oct 25, 2023
Acurx Announces Ibezapolstat Scientific Posters and Presentations at ClostPath 2023 and IDWeek 2023 Scientific Conferences Oct 19, 2023
Acurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection Oct 2, 2023
Acurx Announces Presentation and Update of Its pol IIIC R&D Pipeline at the World Antimicrobial Resistance Scientific Congress Sep 12, 2023
Acurx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 11-13, 2023 Aug 22, 2023
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update Aug 14, 2023
Acurx Pharmaceuticals to Discuss Second Quarter 2023 Financial Results and Provide Business Update Jul 24, 2023
